1. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
- Author
-
van Capelleveen, Julian C., Lee, Sang-Rok, Verbeek, Rutger, Kastelein, John J.P., Wareham, Nicholas J., Stroes, Erik S.G., Hovingh, G. Kees, Khaw, Kay-Tee, Boekholdt, S. Matthijs, Witztum, Joseph L., and Tsimikas, Sotirios
- Subjects
CORONARY heart disease risk factors ,LIPID analysis ,CORONARY disease ,ANTILIPEMIC agents ,APOLIPOPROTEINS ,C-reactive protein ,CHOLESTEROL ,DIABETES ,ENZYME-linked immunosorbent assay ,HIGH density lipoproteins ,HYPERTENSION ,LIPOPROTEINS ,LONGITUDINAL method ,LOW density lipoproteins ,RISK assessment ,SMOKING ,TRIGLYCERIDES ,BODY mass index ,DIAGNOSIS - Abstract
Background Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. Objective To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. Methods apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of "total apoCIII-apoB" and "total apoCIII-apoAI" were derived by multiplying plasma apoB and apoAI, respectively. Results apoCIII-apoB (P =.001), apoCIII-Lp(a) (P <.001), apoCIII-apoAI (P =.005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P <.001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. Conclusions This study suggests that enzyme-linked immunoassay–measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events. Highlights • High-throughput enzyme-linked immunoassays were developed to measure lipoprotein-associated apolipoprotein C-III (apoC-III) levels. • apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI were measured in EPIC-Norfolk. • apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI reflect atherogenic lipid particles. • apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI do not independently predict risk of coronary artery disease events. • Their role in patients with prior history of coronary artery disease needs to be evaluated. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF